Syncom Formu (I) Ltd

SYNCOMF NSE Healthcare Pharmaceuticals
₹19.59
+1.71%
Delayed · cached 15 min

Fair value analysis

SYNCOMF
Syncom Formu (I) Ltd
HealthcarePharmaceuticals
₹19.26
Close used for this calculation
₹19.45Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
65/100
Profitability23/25
Returns13/25
Balance Sheet17/25
Efficiency12/25
Growth14/25
Strong
Quality radar
65Prof.23/25Ret.13/25Eff.12/25B.Sht17/25Growth14/25

Consensus fair value

₹19.45
Near FV
▲ +1.0% against the close used
Model range ₹9.61 – ₹36.48
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear₹9.61Fair value₹19.45Bull₹36.48
FairClose
52-week traded range
52W low ₹10.3052W high ₹21.39

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading close to the consensus fair value

Syncom Formu (I) Ltd closed at ₹19.26, 1.0% below the consensus fair value of ₹19.45 drawn from 8 valuation models.

Financial DNA score 65/100 — Strong. P/E of 21.4x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation
₹9.61
-50.1%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Formula
₹36.48
+89.4%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=20%, FD=7%
P/E Fair Value
₹28.92
+50.1%
EPS × 35.7x (sector P/E)
EPS=0.81, Sector P/E=35.7x
Peter Lynch (PEG)
₹20.25
+5.1%
EPS × Growth% (PEG = 1 is fair)
EPS=0.81, g=25%
EV/EBITDA
₹15.91
-17.4%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=840M
Book Value (P/B)
₹17.40
-9.7%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=4.9, ROE=20.2%, g=6%, r=10%
Reverse DCF
₹19.26
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 9.5% | Historical: 25%
Margin of Safety
₹18.75
-2.6%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=25, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Educational data only. Not a recommendation to buy, sell or hold any security.